Secondary Logo

Most Popular Articles

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY

Potkin, Steven G.; Loze, Jean-Yves; Forray, Carlos; More

International Clinical Psychopharmacology. 32(3):147-154, May 2017.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

Fineberg, Naomi A.; Baldwin, David S.; Drummond, Lynne M.; More

International Clinical Psychopharmacology. 33(6):334-348, November 2018.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study

Clayton, Anita H.; Durgam, Suresh; Li, Dayong; More

International Clinical Psychopharmacology. 32(1):27-35, January 2017.

The reliability and validity of a newly developed self-rating functional scale compared with Personal and Social Performance Scale and World Health Organization Disability Assessment Schedule II

Zhao, Yan-Jie; He, Yan-Ling; Zhang, Li-Li; More

International Clinical Psychopharmacology. 34(1):37-44, January 2019.

Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review

Albert, Umberto; Carmassi, Claudia; Cosci, Fiammetta; More

International Clinical Psychopharmacology. 31(5):249-258, September 2016.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison

Pae, Chi-Un; Wang, Sheng-Min; Han, Changsu; More

International Clinical Psychopharmacology. 32(5):235-248, September 2017.

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Boulenger, Jean-Philippe; Loft, Henrik; Olsen, Christina Kurre

International Clinical Psychopharmacology. 29(3):138-149, May 2014.

The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study

Höfer, Peter; Schosser, Alexandra; Calati, Raffaella; More

International Clinical Psychopharmacology. 31(1):1-7, January 2016.

Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia

Suzuki, Takefumi; Uchida, Hiroyuki; Tanaka, Kenji F.; More

International Clinical Psychopharmacology. 18(6):323-329, November 2003.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; More

International Clinical Psychopharmacology. 30(6):320-328, November 2015.

Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression

Gobbi, Gabriella; Ghabrash, Maykel F.; Nuñez, Nicolas; More

International Clinical Psychopharmacology. 33(1):34-43, January 2018.

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

Singh, Arun; Gopal, Srihari; Kim, Edward; More

International Clinical Psychopharmacology. 33(4):213-216, July 2018.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

Hartford, James; Kornstein, Susan; Liebowitz, Michael; More

International Clinical Psychopharmacology. 22(3):167-174, May 2007.

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials

Thase, Michael E.; Edwards, John; Durgam, Suresh; More

International Clinical Psychopharmacology. 32(5):281-288, September 2017.

Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial

Mico’, Umberto; Bruno, Antonio; Pandolfo, Gianluca; More

International Clinical Psychopharmacology. 26(6):303-310, November 2011.